دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Rheumatic Aortic Stenosis
AmgadMentiasMD, MScaMarwanSaadMD, PhDbMilind Y.DesaiMDaAmarKrishnaswamyMDaVenuMenonMDaPhillip A.HorwitzMDcSamirKapadiaMDaMary VaughanSarrazinPhDcd
doi : 10.1016/j.jacc.2021.02.032
Volume 77, Issue 14, 13 April 2021, Pages 1703-1713
Patients with rheumatic aortic stenosis (AS) were excluded from transcatheter aortic valve replacement (TAVR) trials.
TAVR for Patients With Rheumatic Heart Disease: Opening the Door for the Many??
PeterZillaMD, PhDabcDavid F.WilliamsPhDdDeonBezuidenhoutPhDa
doi : 10.1016/j.jacc.2021.02.044
Volume 77, Issue 14, 13 April 2021, Pages 1714-1716
Long-Term Cardiovascular Outcomes in Systemic Lupus Erythematosus
AdelinaYafasovaMDaEmil L.Fosb?lMD, PhDaMortenSchouMD, DMScbBoBaslundMD, PhDcMikkelFaurschouMD, DMSccKieran F.DochertyMBChBdPardeep S.JhundMBChB, PhDdJohn J.V.McMurrayMDdGuoliSunMDaS?ren L.KristensenMD, PhDaChristianTorp-PedersenMD, DMSceLarsK?berMD, DMScaJawad H.ButtMDa
doi : 10.1016/j.jacc.2021.02.029
Volume 77, Issue 14, 13 April 2021, Pages 1717-1727
Data on long-term cardiovascular outcomes in systemic lupus erythematosus (SLE) are sparse.
Cardiovascular Outcomes in Systemic Lupus Erythematosus: Are We Dropping the Anchor or Dropping the Ball??
TamerSallamMD, PhD
doi : 10.1016/j.jacc.2021.02.054
Volume 77, Issue 14, 13 April 2021, Pages 1728-1730
Myocardial Angiotensin Metabolism in End-Stage Heart Failure
NoemiPavoMD, PhDaSuriyaPrausmüllerMDaGeorgSpinkaMDaGeorgGoliaschMD, PhDaPhilipp E.BartkoMD, PhDaRaphaelWurmMDbHenrikeArfstenMDaGuidoStrunkMSc, PhDcdeMarkoPoglitschMSc, PhDfOliverDomenigMSc, PhDfJuliaMascherbauerMDgKezibanUyanik-?nalMDhChristianHengstenbergMDaAndreasZuckermannMDhMartinHülsmannMDa
doi : 10.1016/j.jacc.2021.01.052
Volume 77, Issue 14, 13 April 2021, Pages 1731-1743
The myocardium exhibits an adaptive tissue-specific renin-angiotensin system (RAS), and local dysbalance may circumvent the desired effects of pharmacologic RAS inhibition, a mainstay of heart failure with reduced ejection fraction (HFrEF) therapy.
National and Local Politics of the Heart?
James L.JanuzziJr.MDaLynne W.StevensonMDb
doi : 10.1016/j.jacc.2021.02.053
Volume 77, Issue 14, 13 April 2021, Pages 1744-1746
Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction
Domingo A.Pascual-FigalMD, PhDabcAntoniBayes-GenisMD, PhDcdMiriamD?ez-D?ezMScb?lvaroHern?ndez-VicenteBScaDavidV?zquez-AndrésMDaJorgede la BarreraMScbEnriqueVazquezMScbAnaQuintasPhDbMar?a A.ZuriagaPhDbMari C.Asensio-L?pezPhDaAnaDopazoPhDbF?timaS?nchez-CaboPhDbJosé J.FusterPhDb
doi : 10.1016/j.jacc.2021.02.028
Volume 77, Issue 14, 13 April 2021, Pages 1747-1759
Clonal hematopoiesis driven by somatic mutations in hematopoietic cells, frequently called clonal hematopoiesis of indeterminate potential (CHIP), has been associated with adverse cardiovascular outcomes in population-based studies and in patients with ischemic heart failure (HF) and reduced left ventricular ejection fraction (LVEF). Yet, the impact of CHIP on HF progression, including nonischemic etiology, is unknown.
Impact of Clonal Hematopoiesis in Ischemic and Nonischemic Heart Failure?
Michael J.RauhMD, PhD
doi : 10.1016/j.jacc.2021.02.045
Volume 77, Issue 14, 13 April 2021, Pages 1760-1762
Team-Based Care of Women With Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 1/5
Melinda B.DavisMDaKatherineArendtMDbNatalie A.BelloMD, MPHcHaywoodBrownMDdJoanBrillerMDeKellyEppsMDfLisaHollierMDgElizabethLangenMDhKiParkMDiMary NorineWalshMDjDominiqueWilliamsMDkMalissaWoodMDlCandice K.SilversidesMDmKathryn J.LindleyMDkAmerican College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group
doi : 10.1016/j.jacc.2021.02.033
Volume 77, Issue 14, 13 April 2021, Pages 1763-1777
The specialty of cardio-obstetrics has emerged in response to the rising rates of maternal morbidity and mortality related to cardiovascular disease (CVD) during pregnancy. Women of childbearing age with or at risk for CVD should receive appropriate counseling regarding maternal and fetal risks of pregnancy, medical optimization, and contraception advice. A multidisciplinary cardio-obstetrics team should ensure appropriate monitoring during pregnancy, plan for labor and delivery, and ensure close follow-up during the postpartum period when CVD complications remain common. The hemodynamic changes throughout pregnancy and during labor and delivery should be considered with respect to the individual cardiac disease of the patient. The fourth trimester refers to the 12 weeks after delivery and is a key time to address contraception, mental health, cardiovascular risk factors, and identify any potential postpartum complications. Women with adverse pregnancy outcomes are at increased risk of long-term CVD and should receive appropriate education and longitudinal follow-up.
Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 2/5
Kathryn J.LindleyMDaC. NoelBairey MerzMDbAnita W.AsgarMD, MSccNatalie A.BelloMD, MPHdSonalChandraMDeMelinda B.DavisMDfMardiGomberg-MaitlandMD, MScgMarthaGulatiMD, MShLisa M.HollierMDiEric V.KriegerMDjKiParkMDkCandiceSilversidesMDlNatasha K.WolfeMDaCarl J.PepineMDkAmerican College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group
doi : 10.1016/j.jacc.2021.02.026
Volume 77, Issue 14, 13 April 2021, Pages 1778-1798
Maternal morbidity and mortality continue to rise in the United States, with cardiovascular disease as the leading cause of maternal deaths. Congenital heart disease is now the most common cardiovascular condition encountered during pregnancy, and its prevalence will continue to grow. In tandem with these trends, maternal cardiovascular health is becoming increasingly complex. The identification of women at highest risk for cardiovascular complications is essential, and a team-based approach is recommended to optimize maternal and fetal outcomes. This document, the second of a 5-part series, will provide practical guidance from pre-conception through postpartum for cardiovascular conditions that are predominantly congenital or heritable in nature, including aortopathies, congenital heart disease, pulmonary hypertension, and valvular heart disease.
Management of Women With Acquired Cardiovascular Disease From Pre-Conception Through Pregnancy and Postpartum: JACC Focus Seminar 3/5
KiParkMDaC. NoelBairey MerzMDbNatalie A.BelloMDcMelindaDavisMDdClaireDuvernoyMDdIslam Y.ElgendyMDeKeith C.FerdinandMDfAfshanHameedMDgDiptiItchhaporiaMDhMargo B.MinissianPhDbHarmonyReynoldsMDiPujaMehtaMDjAndrea M.RussoMDkRashmee U.ShahMD, MSlAnnabelle SantosVolgmanMDmJanetWeiMDbNanette K.WengerMDjCarl J.PepineMDa…Kathryn J.LindleyMDn
doi : 10.1016/j.jacc.2021.01.057
Volume 77, Issue 14, 13 April 2021, Pages 1799-1812
Acquired cardiovascular conditions are a leading cause of maternal morbidity and mortality. A growing number of pregnant women have acquired and heritable cardiovascular conditions and cardiovascular risk factors. As the average age of childbearing women increases, the prevalence of acute coronary syndromes, cardiomyopathy, and other cardiovascular complications in pregnancy are also expected to increase. This document, the third of a 5-part series, aims to provide practical guidance on the management of such conditions encompassing pre-conception through acute management and considerations for delivery.
Diagnostic Cardiovascular Imaging and Therapeutic Strategies in Pregnancy: JACC Focus Seminar 4/5
Natalie A.BelloMD MPHaC. NoelBairey MerzMDbHaywoodBrownMDcMelinda B.DavisMDdNeal W.DickertMD, PhDefStephanie C.El HajjMDghCindyGiullianAPRNiOdaymeQuesadaMDbjKiParkMDkRupa M.SanghaniMDlLesleeShawPhDmAnnabelle SantosVolgmanMDlNanette K.WengerMDnDominiqueWilliamsMDoCarl J.PepineMDkKathryn J.LindleyMDoAmerican College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group
doi : 10.1016/j.jacc.2021.01.056
Volume 77, Issue 14, 13 April 2021, Pages 1813-1822
The prevalence of cardiovascular disease (CVD) in pregnancy, both diagnosed and previously unknown, is rising, and CVD is a leading cause of maternal morbidity and mortality. Historically, women of child-bearing potential have been underrepresented in research, leading to lasting knowledge gaps in the cardiovascular care of pregnant and lactating women. Despite these limitations, clinicians should be familiar with the safety of frequently used diagnostic and therapeutic interventions to adequately care for this at-risk population. This review, the fourth of a 5-part series, provides evidence-based recommendations regarding the use of common cardiovascular diagnostic tests and medications in pregnant and lactating women.
Contraception and Reproductive Planning for Women With Cardiovascular Disease: JACC Focus Seminar 5/5
Kathryn J.LindleyMDaC. NoelBairey MerzMDbMelinda B.DavisMDcTessaMaddenMD, MPHdKiParkMDeNatalie A.BelloMD, MPHfAmerican College of Cardiology Cardiovascular Disease in Women Committee and the Cardio-Obstetrics Work Group
doi : 10.1016/j.jacc.2021.02.025
Volume 77, Issue 14, 13 April 2021, Pages 1823-1834
The majority of reproductive-age women with cardiovascular disease are sexually active. Early and accurate counseling by the cardiovascular team regarding disease-specific contraceptive safety and effectiveness is imperative to preventing unplanned pregnancies in this high-risk group of patients. This document, the final of a 5-part series, provides evidence-based recommendations regarding contraceptive options for women with, or at high risk for, cardiovascular disease as well as recommendations regarding pregnancy termination for women at excessive cardiovascular mortality risk due to pregnancy.
Molecular Imaging Identifies Fibroblast Activation Beyond the Infarct Region After Acute Myocardial Infarction
JohannaDiekmannMD†TobiasKoenigMD†CarolinZwadloMDThorstenDerlinMDJonasNeuserMDJames T.ThackerayPhDAndreasSch?ferMDTobias L.RossPhDJohannBauersachsMDFrank M.BengelMD
doi : 10.1016/j.jacc.2021.02.019
Volume 77, Issue 14, 13 April 2021, Pages 1835-1837
Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial
IlariaCavallariMD, PhDDeepak L.BhattMD, MPHPh. GabrielStegMDLawrence A.LeiterMDDarren K.McGuireMD, MHScOfriMosenzonMDKyungahImPhDItamarRazMDEugeneBraunwaldMDBenjamin M.SciricaMD, MPH
doi : 10.1016/j.jacc.2021.02.030
Volume 77, Issue 14, 13 April 2021, Pages 1837-1840
The Prognostic Role of Triglycerides Should Be Revisited
PanagiotaPietriMDGeorgeGeorgiopoulosMDChristodoulosStefanadisMD
doi : 10.1016/j.jacc.2020.12.068
Volume 77, Issue 14, 13 April 2021, Pages 1840-1841
Remnant Cholesterol Is Just Another Word for Triglycerides When Calculating LDL-C Using the Friedewald Formula
TamasSzili-TorokBScUwe J.F.TietgeMD, PhD
doi : 10.1016/j.jacc.2021.01.053
Volume 77, Issue 14, 13 April 2021, Page 1841
Reply: Usefulness of Circulating Triglycerides and Estimated Remnant Cholesterol as Predictors of Cardiovascular Risk
OlgaCasta?erMD, PhDEmilioRosMD, PhDXavierPint?MD, PhDEmilioOrtegaMD, PhDMontserratFitoMD, PhD
doi : 10.1016/j.jacc.2021.02.010
Volume 77, Issue 14, 13 April 2021, Pages 1841-1843
